Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards

Rhea-AI Filing Summary

Bioventus Inc. senior vice president and general counsel Anthony D'Adamio reported multiple equity compensation transactions in Class A common stock and related derivatives. On March 13, 2026, he received grants of 83,000 restricted stock units (RSUs) and 92,000 stock options with an exercise price of $8.62 per share, expiring on March 13, 2036. Each RSU represents a right to receive one share of Class A common stock. The RSUs and options granted in 2025 and 2026 vest in four equal annual installments beginning on March 15, 2025 and March 15, 2026, subject to his continued service. On the same 2026 date, he exercised 8,886 and 8,750 RSUs into the same number of Class A shares, and the company withheld 3,861 and 3,802 shares at a price of $8.62 per share to cover tax obligations. Following these transactions, he directly owned 148,042 shares of Bioventus Class A common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'Adamio Anthony

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/13/2026		M		8,886	A	$0	146,955	D
Class A Common Stock	03/13/2026		F		3,861	D	$8.62	143,094	D
Class A Common Stock	03/13/2026		M		8,750	A	$0	151,844	D
Class A Common Stock	03/13/2026		F		3,802	D	$8.62	148,042	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/14/2025		A		35,000		(2)	(2)	Class A Common Stock	35,000	$0	35,000	D
Stock Option (Right to Buy)	$9.61	03/14/2025		A		40,000		(2)	03/14/2035	Class A Common Stock	40,000	$0	40,000	D
Restricted Stock Units	(1)	03/13/2026		A		83,000		(3)	(3)	Class A Common Stock	83,000	$0	83,000	D
Stock Option (Right to Buy)	$8.62	03/13/2026		A		92,000		(3)	03/13/2036	Class A Common Stock	92,000	$0	92,000	D
Restricted Stock Units	(1)	03/13/2026		M			8,886	(4)	(4)	Class A Common Stock	8,886	$0	0	D
Restricted Stock Units	(1)	03/13/2026		M			8,750	(2)	(2)	Class A Common Stock	8,750	$0	26,250	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2025, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

3. The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of March 15, 2026, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

4. The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023.

Remarks:

	/s/ Anthony D'Adamio	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Bioventus (BVS) grant to Anthony D'Adamio?

Bioventus granted Anthony D'Adamio 83,000 restricted stock units and 92,000 stock options at an exercise price of $8.62 per share. These awards are part of his equity compensation and each RSU represents one share of Class A common stock upon settlement.

How do Anthony D'Adamio’s new Bioventus (BVS) RSUs and options vest?

The RSUs and options granted in 2025 and 2026 vest in four equal installments on each of the first four anniversaries of March 15, 2025 and March 15, 2026. Vesting is conditioned on D'Adamio continuing in service through each applicable vesting date.

Did Anthony D'Adamio exercise any Bioventus (BVS) restricted stock units?

Yes. On March 13, 2026, he exercised 8,886 and 8,750 restricted stock units into the same number of Class A common shares. These transactions convert previously granted RSUs into actual shares as part of his ongoing equity compensation.

Why were some Bioventus (BVS) shares disposed of in Anthony D'Adamio’s Form 4?

Bioventus withheld 3,861 and 3,802 Class A shares from Anthony D'Adamio at $8.62 per share to pay tax obligations tied to equity vesting and exercises. These F-code dispositions reflect tax withholding, not open-market sales by the executive.

How many Bioventus (BVS) Class A shares does Anthony D'Adamio now hold directly?

After the reported transactions on March 13, 2026, Anthony D'Adamio directly owned 148,042 shares of Bioventus Class A common stock. This figure reflects his position after RSU exercises and share withholdings for associated tax liabilities.

What earlier Bioventus (BVS) equity grants to Anthony D'Adamio are disclosed?

The filing notes a 35,000 RSU grant and 40,000 stock options at $9.61 per share on March 14, 2025. It also references an original grant of 35,545 RSUs vesting in four approximately equal annual installments beginning on March 14, 2023.